Dyslipidemia is one of the most common and ... Moreover, compared with imported PCSK9 monoclonal antibodies on the market, tafolecimab could be dosed in longer interval. I hope tafolecimab will ...

in adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated. Ongericimab has become China’s first domestic PCSK9-targeted ...

Dyslipidemia, specifically the increase of ... Unfortunately, there are only two imported ant-PCSK9 monoclonal antibodies currently approved for marketing in China, and no domestic anti-PCSK9 ...

Dyslipidemia, characterized by elevated ... meet the clinical needs in patients with hyperlipidemia. Anti-PCSK9 monoclonal antibody has a mechanism of action different from existing lipid-lowering ...